<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363322">
  <stage>Registered</stage>
  <submitdate>4/01/2013</submitdate>
  <approvaldate>11/02/2013</approvaldate>
  <actrnumber>ACTRN12613000158763</actrnumber>
  <trial_identification>
    <studytitle>Evaluating treatment efficacy of citalopram, symbiotic, and mebeverine for children with functional abdominal pain.</studytitle>
    <scientifictitle>Evaluation treatment efficacy of citalopram, synbiotic, and mebeverine for children with functional abdominal pain; a randomized, placebo-controlled study.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>391299</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Children's functional abdominal pain</healthcondition>
    <healthcondition>Children mental health</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Other mental health disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>In citalopram group children take oral citalopram tablet 10 mg/day for one week and then 20 mg/day for three weeks. 
In mebeverine group children take oral mebeverine tablet 135 mg/twice daily for four weeks.
In symbiotic group children take oral Lactol tablet (150 million spores + 100 mg FOS) twice daily for four weeks. 
In placebo group children take oral placebo tablet twice daily for four weeks. </interventions>
    <comparator>One placebo tablet( identical in taste and appearance to citalopralm,Lactol and mebeverin but without the active ingredient)  twice a day for 4weeks</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Clinical Global Impression-Global Improvement (CGI-I)

For detecting the abdominal pain improvement.</outcome>
      <timepoint>At the end of treatment (week four)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>clinical Global Impression-severity(CGI-S)

 To detect changing in severity of abdominal pain</outcome>
      <timepoint>At the end of 4 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Wang-Baker Faces Pain Rating Score

To detect changing in abdominal pain rate</outcome>
      <timepoint>At the end of four weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Clinical Global Impression-Global Improvement (CGI-I)

For detecting the abdominal pain improvement</outcome>
      <timepoint>12 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>clinical Global Impression-severity(CGI-S)

 To detect changing in severity of abdominal pain</outcome>
      <timepoint>12 weeks after the end of treatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Wang-Baker Faces Pain Rating Score

To detect changing in abdominal pain rate</outcome>
      <timepoint>12 weeks afte the e d of treatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Children between 6 to 18 years old, having functional abdominal pain according to ROME III criteria, having not consumption of probiotics and antibiotics in previous 2 months</inclusivecriteria>
    <inclusiveminage>6</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>18</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Having gasterointestinal problems rather than functional abdomainal pain, 
 
Patients who will not use three tablets</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>False</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2 / Phase 3</phase>
    <anticipatedstartdate>29/11/2012</anticipatedstartdate>
    <actualstartdate>25/03/2013</actualstartdate>
    <anticipatedenddate />
    <actualenddate>16/12/2013</actualenddate>
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Iran, Islamic Republic Of</country>
      <state>Isfahan</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Isfahan University of medical silences</primarysponsorname>
    <primarysponsoraddress>Isfahan university of medical siences, Hezarjarib Ave,Isfahan,Iran

Postcode: 81647-2384</primarysponsoraddress>
    <primarysponsorcountry>Iran, Islamic Republic Of</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Isfahan university of medical siences</fundingname>
      <fundingaddress>Isfahan university of medical siences, Hezarjaribj Ave Isfahan,Iran

Postcode: 81647-2384</fundingaddress>
      <fundingcountry>Iran, Islamic Republic Of</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other</sponsortype>
      <sponsorname>Child health promotion research center</sponsorname>
      <sponsoraddress>Emam hosein children hospital,Emam Khomeini Ave, Isfahan ,Iran.

Post code :81577-2342</sponsoraddress>
      <sponsorcountry>Iran, Islamic Republic Of</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objective of this study is to evaluate the effect of citalopram, mebeverine, and synbiotic on children functional abdominal pain. This study is randomized - placebo controlled trial. Children age 6 to 18 year old with functional abdominal pain will be assigned in to four groups of 50 person each. Group one: will receive citalopram 10 mg/day in first week and 20 mg/day for fallowing 3 weeks. Group2: children will take 270 mg/day mebeverine for four weeks. Group3: Children in this group will consume Lactol (300 million spores plus 200 mg FOS) for four weeks. In control group children take placebo for four weeks. Clinical Global Impression for severity (CGI-s) and Wang-Baker Faces pain Rating will be measured at the baseline and at the end of treatment (week four) and at the end of study (12weeks latter) also Clinical Global Impression for Improvement CGI-I will be measured at week four and week 12. patients will be followed up at week 2 by phone and at week four and 12 be interviewed and physical examination will be done to evaluate medical tolerance and drug side effects </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics committe of Isfahan University of Medical Sciences</ethicname>
      <ethicaddress>Isfahan university of medical sciences,Hejarjarib Ave,Isfahan,Iran

Post code:81647-2384</ethicaddress>
      <ethicapprovaldate>6/09/2012</ethicapprovaldate>
      <hrec>391299</hrec>
      <ethicsubmitdate>6/08/2012</ethicsubmitdate>
      <ethiccountry>Iran, Islamic Republic Of</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Zahra Pourmoghaddas</name>
      <address>Emam Hosein Children Hospital,Emam Khomeini Ave, Aisfahan,Iran

Post code:81577-2342</address>
      <phone>+989131864168</phone>
      <fax />
      <email>Zahrapormoghadas@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Zahra Pourmoghaddas</name>
      <address>Emam Hosein Children Hospital,Emam Khomeini Ave, Aisfahan,Iran

81577-2342</address>
      <phone>+989131864168</phone>
      <fax />
      <email>Zahrapormoghadas@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Zahra pourmoghaddas</name>
      <address>Emam Hosein Children Hospital,Emam Khomeini Ave, Aisfahan,Iran
Post cod:81577-2342</address>
      <phone>+989131864168</phone>
      <fax />
      <email>Zahrapormoghadas@yahoo.com</email>
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Zahra Pourmoghaddas</name>
      <address> Emam Hosein Children Hospital,Emam Khomeini Ave, Isfahan,iran.

Post code:81577-2342</address>
      <phone>+989131864168</phone>
      <fax />
      <email>Zahrapormoghadas@yahoo.com</email>
      <country>Iran, Islamic Republic Of</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>